泰瑞沙Tagrisso（奥斯替尼osimertinib）

Indications and uses
Tagrisso is a kinase inhibitor indicated for the use of EGFR TKIs in patients with epidermal growth factor receptor (EGFR) metastases when T790M mutation-positive non-small cell lung cancer (NSCLC) is detected using an FDA-approved test. Treatment of patients who have progressed on or after treatment.
This indication was approved under the accelerated approval process based on tumor response rate and response time. Continued approval for this indication may be dependent on confirmation and description of clinical benefit in confirmatory trials.

Dosage and Administration
⑴ Confirm the presence of T790M mutation in tumor specimens before initiating treatment with TAGRISSO.
⑵ Only 80 mg orally administered once daily, with or without food.

Dosage forms and specifications
Tagrisso is available in tablet form, available in 80 mg and 40 mg sizes, with 30 tablets per box.